GSK CFO Interviewed on Q1 Results 2014

LONDON, April 30, 2014 /PRNewswire/ --

The global healthcare company GSK has unveiled 2014 Q1 results today, described by its CFO Simon Dingemans as encouraging across many areas mixed with some challenges, most notably in the US.

As a result, group sales fell in the quarter but the company managed to post bottom line growth of 2% as a result of operating leverage and financial efficiencies. The group declared a 6% increase in the dividend.

The period also saw the significant push by the company to rebalance its portfolio with the proposed asset swap with Novartis.   

The interview and transcript are available now on http://video.merchantcantos.com/companies/g/glaxosmithkline/

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-(0)207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.